Clopidogrel and the concept of high-risk pharmacokinetics.
Roden
Dan M
DM
Stein
C Michael
CM
D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D002986:Clinical Trials as Topic; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19; D014644:Genetic Variation; D006801:Humans; D010597:Pharmacogenetics; D010975:Platelet Aggregation Inhibitors / Q000493:pharmacokinetics* / Q000633:toxicity; D012307:Risk Factors; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000633:toxicity
D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine